Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04495140
Recruitment Status : Completed
First Posted : July 31, 2020
Last Update Posted : November 25, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of PF-06882961 and fraction absorbed of [14C]PF-06882961 in reference to intravenous [14C]PF-06882961 in healthy male participants.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: [14C]PF-06882961, 50 mg Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06882961
Actual Study Start Date : July 22, 2020
Actual Primary Completion Date : October 15, 2020
Actual Study Completion Date : October 15, 2020

Arm Intervention/treatment
Experimental: Oral [14C]PF-06882961, 50 mg
In this arm, a single oral dose of [14C]PF-06882961, 50 mg will be administered as a liquid formulation.
Drug: [14C]PF-06882961, 50 mg
A single oral dose of [14C]PF-06882961, will be administered as a liquid formulation.

Experimental: Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug
In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961, 100 ug, will be administered via intravenous infusion.
Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961 will be administered via intravenous infusion.




Primary Outcome Measures :
  1. Total recovery of radioactivity in urine and feces, following oral administration of [14C] PF-06882961 in period 1 [ Time Frame: Baseline through approximately hour 312 (day 14). Period 1 is 14 days ]
    Total recovery of radioactivity in urine and feces, and both routes combined, expressed as a percent of total oral radioactive dose administered.


Secondary Outcome Measures :
  1. Metabolite profiling/identification in plasma, urine, and feces [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96-312 hour (hr) ]
    Metabolic profiling/identification and determination of relative abundance of [14C]PF-06882961 and the metabolites of [14C]PF-06882961 in plasma, urine, and feces.

  2. Plasma Cmax to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Maximum Observed Plasma Radioactivity

  3. Plasma Tmax to describe the PK of total radioactivity following administration of single, oral dose of [14C]PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Time to Reach Maximum Observed Plasma Radioactivity

  4. Plasma AUClast to describe PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Area under the plasma radioactivity-time profile from time 0 to time of the last quantifiable concentration (Clast)

  5. Plasma AUCinf to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    AUCinf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

  6. Plasma elimination t½ to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 00, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Plasma elimination half-life is the time measured for the plasma radioactivity to decrease by one half.

  7. Plasma Cmax to describe the plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Maximum Observed Plasma Concentration

  8. Plasma Tmax to describe the plasma PK of PF-06882961 following administration of single, oral dose of [14C]PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Time to Reach Maximum Observed Plasma Concentration

  9. Plasma AUClast to describe PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Area under the plasma concentration-time profile from time 0 to time of the last quantifiable concentration (Clast)

  10. Plasma AUCinf to describe plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    AUCinf is Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

  11. Mean residence Time (MRT )following administration of a single, intravenous dose of [14C]PF 06882961 [ Time Frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr ]
    where MRT is the Mean Residence Time

  12. Systemic Clearance (CL) following administration of a single, intravenous dose of [14C]PF 06882961 [ Time Frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr ]
    Systemic clearance, CL is a quantitative measure of the rate at which a drug substance is removed from the body.

  13. Volume of distribution at steady state (Vss) following administration of a single, intravenous dose of [14C]PF 06882961 [ Time Frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr ]
    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

  14. Absolute oral bioavailability (F) [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Absolute oral bioavailability following administration of a single oral dose of PF-06882961 in reference to a single intravenous dose of [14C]PF-06882961

  15. Fraction of dose absorbed following single oral administration of [14C]PF-06882961 [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96-312hr ]
    Fraction absorbed calculated from ratio of total urinary radioactivity following oral administration in reference to intravenous administration

  16. Number of participants with adverse events [ Time Frame: Baseline in Period 1 up to 32 days after the period 2 doses, for a total of approximately 46 days ]
    adverse events

  17. Plasma elimination t½ to describe plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961 [ Time Frame: 00, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr ]
    Plasma elimination half-life is the time measured for the plasma radioactivity to decrease by one half.

  18. Number of participants with safety laboratory test results above/below certain threshold [ Time Frame: baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days) ]
    lab tests

  19. Number of participants with ECG measurements above/below certain threshold [ Time Frame: baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days) ]
    ECGs

  20. Number of participants with vital measurements above/below certain threshold [ Time Frame: baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days) ]
    vitals



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 54 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male participants between 18 to 54 years of age
  • Healthy and capable of signing informed consent document
  • Willing to comply to all scheduled visits, lab tests, lifestyle considerations and study procedures
  • Body mass index (BMI) of 17.5 to 30 kg/m2; and a total body weight ≥50 kg (110 lb).

Exclusion Criteria:

  • acute or chronic medical or psychiatric condition including recent (within the past year)
  • Surgical procedures like gastrectomy, cholecystectomy, Irregularity in bowel movements
  • Use of prescription or non-prescription drugs and dietary and herbal supplements within 14 days prior to the first dose of investigational product.
  • Previous administration with an investigational drug within 60 days (or as determined by the local requirement) preceding the first dose of investigational product used in this study.
  • Known prior participation in a trial involving PF-06882961 or known intolerance to a GLP-1R agonist.
  • A positive urine drug test on screening or Day -1.
  • Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  • Participants with abnormalities in clinical laboratory tests including ECGs, vital signs, liver function tests, myocardial infarction
  • Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
  • History of alcohol or tobacco abuse or binge drinking and/or any other illicit drug use or dependence within past 6 months.
  • Subjects whose occupation requires exposure to radiation or monitoring of radiation exposure.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia only if heparin is planned to flush intravenous catheters.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04495140


Locations
Layout table for location information
Netherlands
PRA Health Sciences
Groningen, Netherlands, 9728 NZ
PRA Health Sciences Utrecht
Utrecht, Netherlands, 3584 BL
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04495140    
Other Study ID Numbers: C3421009
2019-002584-10 ( EudraCT Number )
First Posted: July 31, 2020    Key Record Dates
Last Update Posted: November 25, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
bioavailability
excretion
metabolism
absorption